First- and second-generation EGFR inhibitors designed to target aberrant EGFR activity have significantly impacted outcomes for NSCLC patients whose tumors harbored gain-of-function oncogenic alterations of the receptor gene. This evidence concerns the gene EGFR and non-small cell lung carcinoma.